VYNE Therapeutics

NASDAQ: VYNE
Developing treatments for immuno-inflammatory conditions.

F-Prime Team

Sector

Life Sciences

Category

Therapeutics

Location

Menlo Park, CA

Initial Investment

2015
Developing treatments for immuno-inflammatory conditions.

VYNE Therapeutics (NASDAQ: MNLO) is a late-stage biopharmaceutical company focused on the development and commercialization of serlopitant for the treatment of pruritus (itch) associated with dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis. Formerly Menlo Therapeutics.